Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis

Cancer Research

Volumn 63, Issue 1, 2003, Pages 230-235

  Wall, Nathan R ^a   O'Connor, Daniel S ^a   Plescia, Janet ^a   Pommier, Yves ^b   Altieri, Dario C ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CISPLATIN; DIMETHYL SULFOXIDE; DOXORUBICIN; FLAVOPIRIDOL; MESSENGER RNA; PACLITAXEL; PROTEIN KINASE; PROTEIN P53; SURVIVIN; THREONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ULTRAVIOLET B RADIATION; UTERINE CERVIX CARCINOMA;

EID: 0037228959     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Hengartner. M. O. The biochemistry of apoptosis. Nature (Lond.). 407: 770-776, 2000.
2. Hanahan, D., and Weinberg, R. A., The hallmarks of cancer. Cell, 100: 57-70, 2000.
3. Evan, G. I., and Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature (Lond.). 411: 342-348, 2001.
4. Altieri, D. C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med., 7: 542-547, 2001.
5. Deveraux, Q. L., and Reed, J. C. 1AP family proteins: suppressors of apoptosis. Genes Dev., 13: 239-252, 1999.
6. Hoffman, W. H., Blade, S., Zilfou, J. T., Chen, J., and Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem., 277: 3247-3257, 2002.
7. Bao, R., Connolly, D. C., Murphy, M., Green, J., Weinstein, J. K., Pisarcik, D. A., and Hamilton, T. C. Activation of cancer-specific gene expression by the survivin promoter. J. Natl. Cancer Inst. (Bethesda), 94: 522-528, 2002.
8. Hattori, M., Sakamoto, H., Satoh, K., and Yamamoto, T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett., 169: 155-164, 2001.
9. Islam, A., Kageyama, H., Takada, N., Kawamoto, T., Takayasu, H., Isogai, E., Ohira, M., Hashizume, K., Kobayashi, H., Kaneko, Y., and Nakagawara, A. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene, 19: 617-623, 2000.
10. Olie, R. A., Simoes-Wust, A. P., Baumann, B., Leech, S. H., Fabbro. D., Stahel, R. A., and Zangemeister-Wittke, U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res., 60: 2805-2809, 2000.
11. Andersen, M. H., Pedersen, L. O., Capeller, B., Brocker, E.-B., Becker, J. C., and thor Straten, P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted epitopes in situ as well as ex vivo in cancer patients. Cancer Res., 61: 5964-5968, 2001.
12. Kanwar, J. R., Shen, W, P., Kanwar, R. K., Berg, R. W., and Krissansen, G. W. Effects of survivin antagonists on growth of established tumors and b7-1 immunogene therapy. J. Natl. Cancer Inst. (Bethesda), 93: 1541-1552, 2001.
13. cdc2 phosphorylation of survivin., Proc. Natl. Acad. Sci. USA, 97: 13103-13107, 2000.
14. Grossman, D., Kim, P. J., Schechner, J. S., and Altieri, D. C. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. USA, 98: 635-640, 2001.
15. Mesri, M., Wall, N. R., Li, J., Kim, R. W., and Altieri, D. C. Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Investig., 108: 981-990, 2001.
16. Wang, H. K. Flavopiridol. National Cancer Institute. Curr. Opin. Investig. Drugs, 2: 1149-1155, 2001.
17. Li, F., Ackermann, E. J., Bennett, C. F., Rothermel, A. L., Plescia, J., Tognin, S., Villa, A., Marchisio, P. C., and Altieri, D. C. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol., 1: 461-466, 1999.
18. Li, F., Ambrosini, G., Chu, E. Y., Plescia, J., Tognin, S., Marchisio. P. C., and Altieri, D. C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (Lond.), 396: 580-584, 1998.
19. Vandre, D. D., and Borisy, G. G. Anaphase onset and and dephosphorylation of mitotic phosphoproteins occur concomitantly. J. Cell Sci., 94: 245-258, 1989.
20. Nakagawa, H., Yamamoto, D., Kiyozuka, Y., Tsuta, K., Uemura, Y., Hioki, K., Tsutsui, Y., and Tsubura, A. Effects of genistein and synergistic action in combination with eicosapentaenoic acid on the growth of breast cancer cell lines. J. Cancer Res. Clin. Oncol., 126: 448-454, 2000.
21. Rudner, A. D., and Murray, A. W, The spindle assembly checkpoint. Curr. Opin. Cell. Biol., 8: 773-780, 1996.
22. L. Cell. 87: 619-628, 1996.
23. Ling, Y-H., Tomos, C., and Perez-Soler, R. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J. Biol. Chem., 273: 18984-18991, 1998.
24. Scatena, C. D., Stewart, Z. A., Mays, D., Tang, L. J., Keefer, C. J., Leach, S. D., and Pietenpol, J. A. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J. Biol. Chem., 273: 30777-30784, 1998.
25. 2/M. Mol. Cell. Biol., 19: 8469-8478, 1999.
26. 2/M phases and its role in cell cycle regulation. J. Biol. Chem., 275: 21661-21667, 2000.
27. Breitschopf, K., Haendeler, J., Malchow, P., Zeiher, A. M., and Dimmeler, S. Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol. Cell. Biol., 20: 1886-1896, 2000.
28. Prives, C. Signaling to p53: breaking the MDM2-p53 circuit. Cell. 95: 5-8, 1998.
29. Verdecia, M. A., Huang, H., Dutil. E., Kaiser, D. A., Hunter, T., and Noel, J. P. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat. Struct Biol., 7: 602-608, 2000.
30. Zhao, J., Tenev, T., Martins, L. M., Downward, J., and Lemoine, N. R. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J. Cell Sci., 113 (Part 23): 4363-4371, 2000.
31. Yang, Y., Fang, S., Jensen, J. P., Weissman, A. M., and Ashwell, J. D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli, Science (Wash. DC). 288: 874-877, 2000.
32. Chen, J., Wu, W., Tahir, S. K., Kroeger, P. E., Rosenberg, S. H., Cowsert, L. M., Bennett, F., Krajewski, S., Krajewska, M., Welsh, K., Reed, J. C., and Ng, S. C. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia, 2: 235-241, 2000.
33. Griffin, J. The biology of signal transduction inhibition: basic science to novel therapies. Semin. Oncol., 28: 3-8, 2001.
34. Sausville, E. A., Johnson, J., Alley, M., Zaharevitz, D., and Senderowicz, A. M. Inhibition of CDKs as a therapeutic modality. Ann. N. Y. Acad. Sci. 910: 207-221, discussion 221-202, 2000.
35. Schwartz, G. K., Ilson, D., Saltz, L., O'Reilly, E., Tong, W., Maslak, P., Werner, J., Perkins, P., Stoltz, M., and Kelsen. D. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol., 19: 1985-1992, 2001.
36. Shapiro, G. I., Supko, J. G., Patterson, A., Lynch, C., Lucca, J., Zacarola, P. F., Muzikansky, A., Wright, J. J., Lynch, T. J., Jr., and Rollins. B. J. A Phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin. Cancer Res., 7: 1590-1599, 2001.
37. Patel, V., Senderowicz, A. M., Pinto, D., Jr., Igishi, T., Raffeld, M., Quintanilla-Martinez, L., Ensley, J. F., Sausville, E. A., and Gutkind, J. S. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Investig., 102: 1674-1681, 1998.
38. Arguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M., Kalavar, N. T., Greene, J. F., Jr., Koss, W., Morgan, C. D., Stinson, S. F., Siford, T. J., Alvord, W. G., Klabansky, R. L., and Sausville, E. A. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood, 91: 2482-2490, 1998.
39. Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L. Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., Arbuck, S. G., and Sausville, E. A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol., 16: 2986-2999, 1998.
40. Sausville, E. A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med., 8: S32-S37, 2002.
41. Kitada, S., Zapata, J. M., Andreeff, M., and Reed, J. C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood, 96: 393-397, 2000.
42. Badie, C., Itzhaki, J. E., Sullivan, M. J., Carpenter, A. J., and Porter, A. C. Repression of CDKI and other genes with CDE and CHR promoter elements during DNA damage-induced G2/M arrest in human cells. Mol. Cell. Biol., 20: 2358-2366, 2000.
43. Li, W., Fan, J., and Bertino, J. R. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res., 61: 2579-2582, 2001.
44. cdc2 survival checkpoint in cancer. Cancer Cell, 2: 43-54, 2002.
45. Silke, J., and Vaux, D. L. Two kinds of BIR-containing protein-inhibitors of apoptosis, or required for mitosis. J. Cell Sci., 114: 1821-1827, 2001.
46. Motwani, M., Delohery, T. M., and Schwartz, G. K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on pactitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res., 5: 1876-1883, 1999.
47. Bible, K. C., and Kaufmann, S. H. Cytotoxic synergy between flavopiridol (NSC 649890. L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res., 57: 3375-3380, 1997.
48. Schwartz, G. K., O'Reilly, E., Ilson, D., Saltz, L., Sharma, S., Tong, W., Maslak, P., Stoltz, M., Eden, L., Perkins, P., Endres, S., Barazzoul, J., Spriggs, D., and Kelsen, D. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J. Clin. Oncol., 20: 2157-2170, 2002.